GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: FG-2101 is a non-hydroxamate antibacterial candidate designed to selectively inhibit bacterial UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) and it is one of the compounds claimed in Blacksmith Medicine's patent WO2023055686A1 [2]. FG-2101 is being developed for intravenous and oral routes of administration to treat Gram-negative bacteria infections. The name to structure was confirmed during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego.
|
|
Bioactivity Comments |
FG-2101 is reported to demonstrate nanomolar activity against bacterial LpxC with an IC50 value of ~1 nM [1]. |